SeekingAlpha · Feb 25, 2026
OR
NASDAQ · ORKA
Oruka Therapeutics, Inc.
Healthcare · Biotechnology
$92.20
Up+$1.35 (+1.46%)
Updated Sep 16, 2026, 11:00 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.13B
- P/E ratio
- -12.2
- Dividend yield
- 0.00%
- 52-week range
- $31.32 – $115.52
- Volume
- 784.7K
- Avg. volume
- 480.54K
Price performance
ORKA price history
1M range · 20 trading sessions · Daily adjusted prices
ORKA closed at $92.20 after 20 trading sessions, down 18.46% for the selected period.
- Last close
- $92.20
- Period change
- -18.46%
- Period low
- $90.99
- Period high
- $113.08
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $95.14 | $95.805 | $90.41 | $92.20 | 784.7K |
| Sep 14, 2026 | $92.56 | $97.48 | $92.55 | $95.93 | 773.86K |
| Sep 11, 2026 | $93.40 | $94.29 | $90.48 | $92.38 | 585.3K |
| Sep 10, 2026 | $90.21 | $92.285 | $88.07 | $91.65 | 554.61K |
| Sep 9, 2026 | $93.59 | $94.85 | $91.23 | $91.50 | 524.99K |
| Sep 8, 2026 | $90.06 | $96.435 | $87.676 | $94.31 | 868.27K |
| Sep 4, 2026 | $90.06 | $94.00 | $89.38 | $92.51 | 600.47K |
| Sep 3, 2026 | $91.72 | $93.69 | $90.1185 | $90.99 | 732.6K |
| Sep 2, 2026 | $93.05 | $96.20 | $89.88 | $91.63 | 672.36K |
| Sep 1, 2026 | $90.78 | $93.20 | $90.27 | $92.11 | 596.16K |
| Aug 31, 2026 | $91.00 | $93.88 | $86.00 | $92.62 | 1.29M |
| Aug 28, 2026 | $95.08 | $95.45 | $91.01 | $91.145 | 589.44K |
| Aug 27, 2026 | $98.93 | $99.615 | $96.16 | $96.54 | 614.63K |
| Aug 26, 2026 | $101.30 | $102.48 | $98.2401 | $99.44 | 526.83K |
| Aug 25, 2026 | $104.74 | $106.905 | $100.29 | $101.82 | 1.31M |
| Aug 24, 2026 | $106.75 | $107.225 | $100.64 | $102.42 | 992.28K |
| Aug 21, 2026 | $105.48 | $109.52 | $103.8621 | $107.96 | 935.78K |
| Aug 20, 2026 | $107.72 | $109.005 | $103.14 | $104.86 | 779.27K |
| Aug 19, 2026 | $115.515 | $115.515 | $107.52 | $109.69 | 1.3M |
| Aug 18, 2026 | $110.27 | $113.31 | $109.55 | $113.08 | 574.9K |
Latest ORKA news
The latest Smart Investors Daily articles mentioning ORKA.
Stock researchCompany · Overview
ORKA research
Overview
Company profile and research snapshot.
Company profile
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $49.33
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 3, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 11, 2026 | Guggenheim | Buy | — |
| Aug 11, 2026 | Wedbush | Outperform | — |
| Aug 11, 2026 | BTIG | Buy | — |
| Aug 3, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Jan 5, 2026
Oruka Therapeutics: ORKA-001 For Psoriasis In Focus As 2026 Phase 2 Data Nears
Oruka analysis: ultra-durable psoriasis biologics ORKA-001/002 aim for 1â3 doses/yr with strong efficacy; liquid balance sheet and fair valuation. See more on ORKA.
globenewswire.com · Dec 11, 2025
Oruka Therapeutics Announces New Board Member and Board Transition
Appoints accomplished commercial leader Chris Martin to its Board of Directors Appoints accomplished commercial leader Chris Martin to its Board of Directors
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
